Study study type PathologyT1T0Patientssample sizesROB Results

mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population

versus Standard of Care (SoC)
Ipilimumab (10 mg/kg)
CA184-162, 2017
  NCT01585987
RCTmGC or mGEJC - L2 - all populationipilimumabSoC (maintenance)patients with unresectable locally advanced/ metastatic gastric or gastroesophageal junction (GEJ) cancer who achieved at least stable disease (SD) following first-line treatment with combination platinum-fluoropyrimidine chemotherapy57 / 57some concern
inconclusive
  • statistically significant 59 % increase in progression or deaths (PFS)
  • statistically significant 44 % increase in irPFS (PE)